02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Form 8.5 (EPT/RI) - Bioquell plc

28/08/2015 07:57:51
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY..

Form 8.3 - AXA INVESTMENT MANAGERS S.A.:Royal Dutch Shell Plc

27/08/2015 15:03:21
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

HSBC Bank Plc : Form 8.5 (EPT/RI) - CHIME COMMUNICATIONS PLC

27/08/2015 11:47:35
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
HAVAS 2015 Interim Results: Revenue up 19.2% / Organic growth strong at +6.3% / Profitability up 30 basis points to 13.3%
2
Ethan Allen Comments on Shareholder Letter
3
BARING EMERGING EUROPE PLC - Transaction in Own Shares
4
ASHMORE GLOBAL OPPORTUNITIES LTD - Correction - Half-yearly Report
5
Maurel & Prom : Consolidated income at 30 June 2015

Related stock quotes

GlaxoSmithKline PLC 1,329.75 -0.1% Stock price decreasing
GlaxoSmithKline PLC 40.93 -0.7% Stock price decreasing
Theravance Inc 13.75 -0.5% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 August 2015 15:43:26
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150824.1 - EUROWEB5 - 2015-08-28 16:43:26 - 2015-08-28 15:43:26 - 1000 - Website: OKAY